Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 30, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares, executed in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,600,000 ordinary shares.
- Repurchase Price: 1,119.64 pence per share.
- Treasury Shares Held: 484,194,158 shares (representing 9.00% of total voting rights).
- Shares in Issue: 5,378,046,676 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 1,600,000 shares purchased on April 30, 2008. Consequently, the number of shares held in Treasury increased to 484,194,158. The filing does not provide comparative data for prior periods regarding financial performance or share counts.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and confirms conformity with the Financial Services Authority's Disclosure and Transparency Rules. No specific risks or contingencies are detailed in this text.
Key Facts for Investor Verification
- Verify the total cost of the share repurchase (1,600,000 shares at 1,119.64 pence) against the company's cash position in other filings.
- Confirm the updated total voting rights denominator (5,378,046,676 shares) for compliance with disclosure thresholds.
- Review the impact of the 9.00% Treasury share holding on earnings per share calculations in subsequent financial reports.
- Check the authority granted at the May 23, 2007 AGM to ensure the repurchase was within the approved limits.